Multi-country

WHO is preparing to ration the obesity drug revolution before it becomes another access disaster

CAR-T Starts Moving From Factory Medicine to In-Patient Engineering

AML’s Frontline Future Starts With Finding the Mutation Fast

FSHD Gets a Stronger Biological Signal

ALS Immunotherapy Moves Into the Extension Phase

Europe’s AMR Strategy Depends on the Lab Result Being Right

Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
